What's New in Psoriasis

In a recent update on psoriasis treatments, Mark Lebwell, Dean for Clinical Therapeutics at Mount Sinai, highlighted an expanding arsenal of innovative therapies, with notable advancements in both systemic and oral options. Vimikizumab, finally approved in the US, shows excellent efficacy, achieving 85.7% PASI 100 rates after 96 weeks, and demonstrates prolonged remission, with many patients maintaining remission for up to 44 weeks post-treatment. New developments include the approval of Spisolumab for generalized pustular psoriasis, which rapidly clears 54% of pustules in one week, and an anticipated subcutaneous formulation for maintenance therapy. He also referred to Imcidolumab targeting the IL-36 receptor for generalized pustular psoriasis, alongside others like Secukinumab, which, while effective for arthritis, also benefits counterpart psoriasis. Oral therapies are on the rise, with new anti-IL-23 and IL-17 inhibitors showing promising results, demonstrating biological efficacy without the need for injections. Ducravacitinib, a promising oral TIC2 inhibitor, shows increased effectiveness over time with a favorable safety profile. Meanwhile, Apremilast remains popular due to its tolerability and now shows comparable efficacy in pediatric patients. Lastly, a novel oral PDE4 inhibitor exhibits superior effectiveness compared to previous options, further diversifying treatment strategies for psoriasis patients.